A. Lampo

发表

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

Stephen H Hughes, Peter Williams, Paul J Lewi, 2005, Journal of medicinal chemistry.

Phospholipidosis in Rats Treated with Amiodarone: Serum Biochemistry and Whole Genome Micro-Array Analysis Supporting the Lipid Traffic Jam Hypothesis and the Subsequent Rise of the Biomarker BMP

R. Vries, G. Verheyen, A. Lampo, 2012, Toxicologic pathology.

Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs

G. Mannens, T. Verhaeghe, M. Rouan, 2017, Toxicologic pathology.

Evaluation of miR-122 and Other Biomarkers in Distinct Acute Liver Injury in Rats

J. Snoeys, P. Guzzie‐Peck, J. Sasaki, 2013, Toxicologic pathology.

Toxicological Profile and Safety Evaluation of Antifungal Azole Derivatives

P. Vanparys, A. Lampo, R. Marsboom, 1989, Mycoses.

Differential responses to JNJ‐37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague–Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics

A. Lampo, M. Niehoff, M. Desmidt, 2014, Journal of applied toxicology : JAT.

Commentary on "Hydroxypropyl cyclodextrins: potential synergism with carcinogens".

P. Jacqmin, A. Lampo, L. Lammens, 1997, Journal of pharmaceutical sciences.

Flow cytometric analysis of micronucleated reticulocytes: Time‐ and dose‐dependent response of known mutagens in mice, using multiple blood sampling

P. Vanparys, A. De Smedt, A. Lampo, 2005, Environmental and molecular mutagenesis.

Safety aspects of oral antifungal agents.

P. Vanparys, A. Lampo, R. Marsboom, 1990, British journal of clinical practice. Supplement.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

M. D. de Jonge, H. Arkenau, J. D. de Bono, 2015, Clinical Cancer Research.

Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients

A. Lampo, L. Lammens, M. Engelen, 2019, PLoS neglected tropical diseases.

The Use of Solubilizing Excipients and Approaches to GenerateToxicology Vehicles for Contemporary Drug Pipelines

M. Brewster, M. Noppe, C. Mackie, 2007 .

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

Sally Robinson, Kathryn Chapman, David Dreher, 2008, Regulatory toxicology and pharmacology : RTP.

Challenging the regulatory requirement for conventional acute toxicity studies in pharmaceutical drug development

David Dreher, Kathryn L Chapman, S. Robinson, 2007 .

Optimisation of the cell cultivation methods in the embryonic stem cell test results in an increased differentiation potential of the cells into strong beating myocard cells.

A. K. Peters, P. Vanparys, A. De Smedt, 2008, Toxicology in vitro : an international journal published in association with BIBRA.

Tissue Kim-1 and Urinary Clusterin as Early Indicators of Cisplatin-Induced Acute Kidney Injury in Rats

A. Lampo, N. Goeminne, S. Starckx, 2012, Toxicologic pathology.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

David Dreher, Kathryn L Chapman, M. Festag, 2008, Regulatory toxicology and pharmacology : RTP.